Daily data tracking
Three major indexes: the Shanghai index rose 0.16%, the Shenzhen composite index fell 0.38% and the gem index fell 1.09%
Shenwanyi plate: building materials, household appliances and building decoration rose; Defense industry, nonferrous metals and electrical equipment
Concept sector: the concept of air transportation, household light industry and white appliances rose; Lithium ore, lithography machine, lithium electrolyte
Transaction and northbound capital: the transaction between the two cities was about 11997.7 billion yuan, a decrease compared with the previous trading day, and the net inflow of northbound capital was about 7.949 billion yuan
Hot spot tracking: industry reviews
Growth hormone is a peptide hormone secreted by the anterior pituitary of human body, which is composed of 191 amino acids. Growth hormone exerts its physiological function by stimulating the liver and other tissues to produce insulin-like growth factor-1 (IGF-1), promotes bone growth, promotes anabolism and protein synthesis, promotes lipolysis, inhibits glucose utilization and increases blood glucose. During puberty, growth hormone further causes rapid growth of height under the synergistic effect of sex hormones.
Leading enterprises in China’s growth hormone industry include Changchun High And New Technology Industries (Group) Inc(000661) and Anhui Anke Biotechnology (Group)Co.Ltd(300009) , which account for 90% of China’s growth hormone market share. Among them, Changchun High And New Technology Industries (Group) Inc(000661) is the only growth hormone manufacturer in China with a complete product line of powder injection, water injection and long-term water injection, with a market share of more than 70% in China; The growth hormone market of Anhui Anke Biotechnology (Group)Co.Ltd(300009) accounts for about 15% – 20%. In September 2021, Anhui Anke Biotechnology (Group)Co.Ltd(300009) human growth hormone for injection was approved as an indication for idiopathic short stature, which is the first product approved in China.
The ceiling of growth hormone in China is extremely high. On the one hand, the proportion of Chinese children with dwarfism receiving treatment is low, only 5.7% in 2020. Growth hormone is expected to further improve children’s indications and the penetration rate is increasing; On the other hand, there is a broad market for adult growth hormone, and the market peak is expected to reach 10 billion yuan, The incidence rate of adult growth hormone deficiency (AGHD) is the metabolic disorder caused by the growth hormone synthesis failure in adult pituitary gland and the lack of growth hormone. According to statistics, the incidence of adult growth hormone deficiency is about 2-3/10000. At present, Changchun High And New Technology Industries (Group) Inc(000661) is making efforts to the adult growth hormone market, and the related products are in phase II of the clinical practice.
Although the ceiling of growth hormone is high and the space is broad, there is a risk of abusing the limited quantity and purchasing with quantity.
Clinically, growth hormone has clear indications, At present, the indications of growth hormone in the treatment of short stature mainly include growth hormone deficiency (GHD), chronic renal insufficiency (before renal transplantation), Turner syndrome, Prader Willi syndrome and intrauterine growth retardation (children younger than gestational age) and idiopathic short stature. Therefore, for patients with non short stature, although growth hormone can theoretically help poor children grow tall, it is not recommended to use it beyond the indications. However, some fall into “height anxiety” Parents are superstitious about the role of growth hormone. Under the push of doctors and medical representatives, they frequently use the drugs applied to patients with dwarfism for the increase of healthy children. Since this year, Xinhua news agency and other media have successively issued documents pointing directly at the phenomenon of growth hormone abuse. If the phenomenon of growth hormone abuse is difficult to stop, it will not rule out the possibility of being included in key monitoring in the future.
At the same time, growth hormone will face the risk of price decline caused by centralized purchase in the future. At the end of September, Guangdong Pharmaceutical Trading Center issued the volume procurement document (Exposure Draft) of 153 pharmaceutical groups including diclofenac of Guangdong alliance Guangdong has formed an alliance with 10 provinces and autonomous regions in Shanxi, Jiangxi, Henan, Guangxi, Hainan, Guizhou, Qinghai, Ningxia, Xinjiang and Xinjiang production and Construction Corps to purchase diclofenac and other 153 drug groups in volume. Recombinant human growth hormone for injection and recombinant human growth hormone injection were included.
Risk tip: the stock market is risky and investment should be cautious
